Risankizumab induces radiological healing in treatment-refractory small bowel Crohn's disease

Abstract

Background: Small bowel (SB) Crohn's disease (CD) is a heterogenous condition, ranging from short segments of inflammation in the terminal ileum, to multifocal inflammatory, stricturing or fistulising phenotypes. Up to 80% of patients with CD have SB involvement and symptoms can be debilitating and difficult to treat. Despite the evolving therapeutic armamentarium of CD therapies, efficacy in SB CD remains unclear as SB radiological outcome measures are not routinely reported in clinical trials. Risankizumab has demonstrated efficacy in CD and effectiveness in a realworld setting. We aim to measure radiological improvement in patients with SB CD initiated on risankizumab across four London tertiary centres.